Innopharmax (4172.TWO) Stock Price

Innopharmax Price

CLOSED
10.25
​
Market closed

Over the last 16 years Innopharmax grew revenue by 22.1% annually, reaching 68.99 M TWD. For Innopharmax, the net margin of -267.3% is down versus -193.4% a few years ago.

Innopharmax stock price

Access this data via the Eulerpool API

Innopharmax business model & stock analysis

InnoPharmax, Inc. engages in the development and commercialization of pharmaceutical products for the treatment of oncology and specialty. The company is headquartered in Taipei City, Taipei. The company went IPO on 2012-09-13. The firm mainly provides generic drugs, including Cyclosporine A, Tacrolimus, Imipenem, Cilastatin, Gadodiamide, Gadopentetate, Levodopa, Carbidopa and Entacapone, as well as new drugs, including Gemcitabine Oral, Bendamustine, AB01001 patch and Carvedilol CR, among others. The firm mainly distributes its products within domestic market.

Frequently asked questions about Innopharmax

Converted at the current exchange rate, the Innopharmax share trades at 0.29 EUR (10.25 TWD).

The revenue cannot currently be calculated for Innopharmax.

The profit cannot currently be calculated for Innopharmax.

The P/E ratio cannot be calculated for Innopharmax at the moment.

The P/S cannot be calculated for Innopharmax currently.

The Eulerpool Quality Score for Innopharmax is 3/10.

The ISIN of Innopharmax is TW0004172002. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Innopharmax is 4172.TWO. The ticker symbol is used to trade Innopharmax shares on the stock exchange.

Fair ValueTerminal
9.64 TWD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
2.03 M TWD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Taiwan
Currency
TWD
Initial public offering
Sep 13, 2012
ISIN
TW0004172002
Cusip
Y3990Z101
Market capitalization
1.23 B TWDSmall Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/Se
—
EV/EBIT
—
P/B Ratio
2.92
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-43.99 %
Last updated Oct 8, 2026, 6:16 PM

Innopharmax Peer Group

Innopharmax FIGI

4172:TT (Taipei Stock Exchange) · BBG003CC2VR3

All fundamentals and in-depth analysis of Innopharmax

Our stock analysis for Innopharmax stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Innopharmax. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.